STOCK MARKET BSE NSE

COVID-19: Amid reports of shortage, remdesivir production to be up to 78 lakh vials per month

Last week, the government had put ban on export of Remdesivir for the time being to meet domestic needs.

Published: 15th April 2021 02:43 AM  |   Last Updated: 15th April 2021 08:35 AM   |  A+A-

Remdesivir

Remdesivir. (File Photo)

Express News Service

NEW DELHI: Amid persistent reports of a shortage in availability of Remdesivir, the government on Wednesday announced that it gave fast track approvals to seven additional sites with a production capacity of 10 lakh vials per month. Another 30 lakh vials per month are also in the pipeline to ramp up its production in the country. Currently, seven production sites produce 38.8 lakh vials in a month.

The latest interventions are likely to raise the production capacity to around 78 lakh vials per month in India.

Last week, the government had put ban on export of Remdesivir for the time being to meet domestic needs.

Four lakh vials were being supplied outside every month.

Remdesivir has been part of India’s national Covid treatment protocol as an investigational therapy, despite a WHO study finding the drug “had little or no effect on hospitalized patients with Covid, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay.”

As the second wave of the outbreak in India has catapulted active cases to over 13 lakh within a few weeks, lakhs of patients are desperately seeking the drug which is meant to be available only in hospitals.

Administered over 5 or 10 days, the course of treatment should not exceed Rs 6,000 as each vial is supposed to cost Rs 595. But there are reports that black marketers are fleecing people in need of the injection.

“Manufacturers have volunteered to reduce the price to less than Rs 3,500 by the end of this week, to support the efforts of PM Narendra Modi, to fight against Covid,” the Ministry of chemicals and fertilizers said, adding that the manufactures were directed to give priority to hospital and institutional level supplies.

Enforcement authorities were directed by the DCGI to take immediate action on blackmarketing, hoarding and overcharging of the drug, it said.

The National Pharmaceutical Pricing Authority is continuously monitoring the availability of Remdesivir. On Tuesday, authorities had insisted that the drug should be used only Covid patients in need of oxygen.

Manufacturers step in to help people: Reports

There were reports that manufacturers of Remdesivir have also volunteered to reduce the price to less than Rs 3,500 per vial by the end of this week in order to support the efforts of the government in the fight against second wave of Covid infections



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp